This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Alprazolam

Well Researched

Xanax | High-potency triazolobenzodiazepine | Schedule IV

Aliases (9)

Xanax · Xanax XR · Niravam · alprazolam · 8-chloro-1-methyl-6-phenyl-4H-[1 · 2 · 4]triazolo[4 · 3-a][1 · 4]benzodiazepine

TYPICAL DOSE

0.25-1 mg PRN (max ~4 mg/day in panic disorder …

0.25-1 mg PRN; chronic dosing 0.5-4 mg/day divided BID-QID under prescriber

ROUTE

Oral (immediate-release tablets, ODT, oral solu…

Oral (IR tablets, ODT, oral solution, XR for panic disorder)

CYCLE

PRN only — chronic use risks dependence within …

PRN only for healthy adults; chronic use risks tolerance within weeks and physical dependence within days-weeks

STORAGE

Room temperature, dry, out of reach (high-abuse…

Room temperature, secured (Schedule IV)

Overview

What is Alprazolam?

Alprazolam (Xanax) is a high-potency triazolobenzodiazepine, FDA-approved in 1981 for panic disorder and generalized anxiety disorder. The fused triazole ring distinguishes it from older 1,4-benzodiazepines like diazepam by conferring faster brain penetration (Tmax 1-2 hours) and stronger antipanic action at lower mg-equivalent doses. It is the single most-prescribed and most-misused benzodiazepine in the US (~17M prescriptions/year per IQVIA/DEA ARCOS), and is covered by the 2020 FDA class-wide Boxed Warning on benzodiazepines (abuse, misuse, addiction, dependence, withdrawal) and the 2016 opioid co-prescribing Boxed Warning.

Key Benefits

Rapid-onset acute anxiety + panic-attack relief (30-60 min oral); strong anti-panic action at lower mg-equivalent doses than older benzos; FDA-approved for panic disorder and GAD; effective single-dose rescue tool for documented panic disorder under prescriber.

Mechanism of Action

Positive allosteric modulator at the benzodiazepine binding site of GABA-A receptors (α/γ subunit interface), increasing the FREQUENCY of chloride channel opening when GABA is bound. Non-selective across α1/α2/α3/α5 subunits — α1 mediates sedation and abuse liability, α2/α3 mediate anxiolysis, α5 mediates memory effects. The fused triazole ring confers faster brain penetration than older 1,4-benzodiazepines. Metabolized primarily by CYP3A4 to α-hydroxyalprazolam (minor active) and 4-hydroxyalprazolam (essentially inactive).

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

Research Indications

Most Effective

The binding site

Alprazolam, like every clinical benzodiazepine, does not activate GABA-A receptors directly. It binds an allosteric site at the interface…

Effective

What makes it a triazolobenzodiazepine

The defining structural feature of alprazolam (and triazolam, midazolam, and the synthetic etizolam) is a triazole ring fused to the diaz…

Investigational

Subunit profile and the abuse-liability question

Alprazolam binds α1, α2, α3, and α5 GABA-A subunits with broadly similar affinity — i.e., it is not subunit-selective. The α1 subunit med…

Investigational

Pharmacokinetics

- Tmax (peak plasma): 1-2 hours oral. Sublingual or oral disintegrating tablet (Niravam) is slightly faster (~30-60 min). Xanax XR delays…

Investigational

The "rebound anxiety between doses" phenomenon

Because alprazolam's half-life is ~11 hours but its anxiolytic effect dwindles before plasma levels drop substantially, regular twice-dai…

Investigational

Plain-English summary

Xanax is a fast, strong, short-acting "amplifier" for the brain's main "off" signal (GABA). Each dose hits hard within an hour, lasts abo…

Peptide Interactions

Opioids

Synergistic

(fentanyl, oxycodone, hydrocodone, heroin, methadone, buprenorphine) — respiratory depression, primary overdose-death mechanism. FDA Boxed Warning since 2016…

Alcohol

Synergistic

additive CNS depression and respiratory depression. Common cause of accidental death. Alcohol also induces CYP3A4 in chronic use, complicating PK.

Z-drugs

Synergistic

(zolpidem, zopiclone, eszopiclone) — same GABA-A α1 site, additive sedation and respiratory depression. Do not stack.

Barbiturates

Synergistic

additive at GABA-A; high lethality in combination.

Other CNS depressants

Synergistic

first-generation antihistamines (diphenhydramine, hydroxyzine), tricyclic antidepressants, antipsychotics, gabapentinoids (gabapentin, pregabalin), GABA-B ag…

L-theanine

Avoid

not dangerous but redundant; theanine is a much milder GABAergic/anxiolytic and the alprazolam swamps any theanine effect. Theanine is the better daily anxio…

Magnesium glycinate

Avoid

same logic; magnesium is the better daily lever for GABAergic tone without addiction.

Other benzodiazepines

Avoid

redundant + cumulative risk. If switching benzodiazepines, do it as part of a taper (typically into diazepam for taper purposes), not as a stack.

Phenibut

Avoid

phenibut is a GABA-B + α2δ calcium channel ligand with its own severe withdrawal syndrome; stacking compounds dependence pharmacology.

What to Expect

Onset
30-60 minutes oral; peak effect 1-2 hours. Sublingual (Niravam) ~15-30 min faster.
Acute
(days 1-14): rebound anxiety often *worse than baseline*, insomnia, tremor, sweating, tachycardia, headache, photophobia, hyperacusis, depersonalization, aka…

Side Effects & Safety 14

Side Effects

1Sedation, drowsiness, fatigue (common dose-limiting effect)
2Cognitive impairment (memory, processing speed, attention)
3Reaction time slowing (driving, athletic performance, technique acquisition)
4Ataxia, mild incoordination
5Anterograde amnesia (more common with alprazolam than longer-acting benzodiazepines)
6Inter-dose anxiety / rebound symptoms (the alprazolam-specific signature)
7Tolerance with daily use (fast)
8Paradoxical disinhibition / aggression / agitation (Bond et al. 1995)
9Depression / emotional blunting / anhedonia
10Sexual dysfunction (decreased libido, anorgasmia)
11GI: nausea, dry mouth, constipation
12Headache
13Visual blur
14Hypotension

When to Stop

Severe withdrawal seizures on abrupt cessation — alprazolam has the highest within-class seizure risk after >2 weeks of regular use. Can be fatal.
Delirium in withdrawal (esp. elderly, polypharmacy, high doses)
Respiratory depression in opioid combination (or alcohol, or barbiturate, or Z-drug combination) — primary mechanism of overdose death
Falls and hip fractures, especially in elderly — 50-80% increased risk
Motor vehicle crash at initiation and during chronic use
Suicidal ideation — paradoxical worsening of depression, esp. early in treatment
Protracted withdrawal / BIND — 10-15% of long-term users, 6-18+ months, sometimes years
Counterfeit-pill fentanyl overdose — the dominant 2020s acute-mortality vector for alprazolam-class exposure; not a side effect of the drug itself but of the supply chain
Pregnancy Category D — possible cleft palate signal in first trimester (older data, contested), neonatal withdrawal syndrome with chronic third-trimester exposure, "floppy baby syndrome." Excreted in breast milk; not recommended.
First 2 weeks: elevated fall and MVA risk, sedation peak
Weeks 2-6: tolerance and dependence consolidation; the window in which "PRN for panic" silently becomes "daily for anxiety"
Cessation period: acute withdrawal (1-4 weeks if rapid) then sub-acute (weeks-months); seizure risk peaks days 1-7 of acute withdrawal, faster than for longer-acting benzodiazepines

References

Greenblatt DJ, Wright CE — Clinical pharmacokinetics of alprazolam (J Clin Pharmacol 1989, PMID 2666487)

pubmed.ncbi.nlm.nih.gov · 1989

definitive PK paper, half-life ~11 hours, CYP3A4 metabolism, α-hydroxyalprazolam metabolite characterization

Alprazolam

Overview

What is Alprazolam?

Key Benefits

Mechanism of Action

Pharmacokinetics

Research Indications

The binding site

What makes it a triazolobenzodiazepine

Subunit profile and the abuse-liability question

Pharmacokinetics

The "rebound anxiety between doses" phenomenon

Plain-English summary

Peptide Interactions

What to Expect

Side Effects & Safety 14

Side Effects

When to Stop

References

Greenblatt DJ, Wright CE — Clinical pharmacokinetics of alprazolam (J Clin Pharmacol 1989, PMID 2666487)

Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL — Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013 (Am J Public Health 2016, PMID 26890165)

Olfson M, King M, Schoenbaum M — Benzodiazepine use in the United States (JAMA Psychiatry 2015, PMID 25785970)

Drake CE, Greenwald MK — Trends in alprazolam-related deaths and prescriptions in the United States 2012-2017 (Drug Alcohol Depend 2019, PMID 31085376)

FDA Drug Safety Communication — Boxed Warning for Benzodiazepine Drug Class (Sept 23, 2020)

Alprazolam — StatPearls / NCBI Bookshelf

Xanax (alprazolam) US prescribing information (FDA label)

Ballenger JC, Burrows GD, DuPont RL Jr, et al. — Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment (Arch Gen Psych 1988, PMID 3274369)

Pecknold JC, Swinson RP, Kuch K, Lewis CP — Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects (Arch Gen Psych 1988)

Hooked on benzodiazepines: GABA-A receptor subtypes and addiction (Tan et al., Trends Neurosci 2011, PMC4020178)

Benzodiazepine Pharmacology and CNS Effects (PMC3684331)

The Ashton Manual (Heather Ashton, last revision 2002)

Ashton Manual PDF

ASAM Joint Clinical Practice Guideline on Benzodiazepine Tapering (2025)

DEA Public Safety Alert — One Pill Can Kill (2021, expanded 2022-2024)

DEA 2023 National Drug Threat Assessment

CDC Health Alert Network advisories — counterfeit pill / fentanyl mass-overdose events

Bond AJ — Drug-induced behavioural disinhibition: incidence, mechanisms and therapeutic implications (CNS Drugs 1995)

Long-term neurological consequences following benzodiazepine exposure: A scoping review (PLOS One, 2024)

Huff C, Finlayson AJR, Foster DE, Martin PR — Enduring neurological sequelae of benzodiazepine use: an internet survey (Therapeutic Advances in Psychopharmacology 2023, PMC10331340)

Cross-National Collaborative Panic Study — historical overview (Roy-Byrne 1989)

Alprazolam — Wikipedia

Alprazolam — PsychonautWiki

Bartoli et al. — Pharmacological treatment for panic disorder: NMA (Translational Psychiatry 2025)

GoodRx Alprazolam pricing

See something off?

Related compounds